Background: The use of in vivo dosimetry with thermolumiscent dosimeters (TLDs) as a veritable means of quality control in conventional radiotherapy procedures was determined in this work.

Aim: The objective of this study was to determine the role of in vivo dosimetry with thermoluminescent dosimeters (TLDs) as part of quality control and audit in conventional radiotherapy procedures delivered with Co-60 teletherapy machine.

Subjects And Methods: Fifty-seven patients with cancers of the breast, pelvis, head and neck were admitted for this study. TLD system at the Radiation Monitoring and Protection Centre, Lagos State University, Ojo, Lagos-Nigeria was used for the in vivo entrance dose readings. All patients were treated with Co-60 (T780c) teletherapy machine at 80 cm source to surface distance located at Eko Hospitals, Lagos. Two TLDs were placed on the patient surface within 1 cm from the center of the field of treatment. Build-up material made of paraffin wax with a density of 0.939 g/cm(3) and a thickness 0.5 cm was placed on top of the TLDs. A RADOS RE 200 TLD reader was used to read out the TLDs over 12 s and at a temperature of 300°C.

Results: The results showed that there was no significant difference between the expected dose and measured dose of breast (P = 0.11), H and N (P = 0.52), and pelvis (P = 0.31) patients. Furthermore, percentage difference between expected dose and measured dose of the three treatment sites were not significantly different (P = 0.11). More so, 88.9% (16/18) treated breast, 91.3% (21/23) pelvis, and 86.7% (13/15) H and N patients had percentage deviation difference less than 5%. In general, 89.3% (50/56) patients admitted for this study had their percentage deviation difference below 5% recommended standard limit.

Conclusion: The values obtained establish that there are no major differences from similar studies reported in literature. This study was also part of quality control and audit of the radiotherapy procedures in the center as expected by national and international regulatory bodies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804652PMC
http://dx.doi.org/10.4103/2141-9248.177977DOI Listing

Publication Analysis

Top Keywords

radiotherapy procedures
16
conventional radiotherapy
12
quality control
12
entrance dose
8
thermoluminescent dosimeters
8
procedures delivered
8
delivered co-60
8
co-60 teletherapy
8
teletherapy machine
8
vivo dosimetry
8

Similar Publications

Introduction: This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.

Materials And Methods: 235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated.

View Article and Find Full Text PDF

Objectives: Non-mortality benefits of breast cancer screening are rarely considered in assessments of benefits versus harms. This study aims to estimate the rate of overdiagnosis in women with screen-detected breast cancer (SDBC) by allocating cases to either possibly overdiagnosed (POD) or not overdiagnosed categories and to compare treatment recommendations for surgery and adjuvant treatments by category, age at diagnosis and cancer stage.

Methods And Analysis: Retrospective secondary analysis of 10 191 women diagnosed with breast cancer in Australia and New Zealand in 2018.

View Article and Find Full Text PDF

Background: Recent patient studies have linked higher immune cell doses with worse quality of life and survival. For thoracic radiotherapy, heart dose is a major contributor to the effective dose to immune cells (EDIC).

Purpose: This study investigates heart and immune cell doses for plans optimized using a cardiac-sparing knowledge-based planning (KBP) model and the impact of carefully crafted beam geometry.

View Article and Find Full Text PDF

Objective: To compare health-related quality of life (HRQOL) in patients undergoing radical cystectomy with ileal conduit (RC) or bladder preservation (BP) with (chemo)radiotherapy for bladder cancer.

Methods And Analysis: Patients with bladder cancer, stage cT1-T4, cN0-N1, M0 with a minimum follow-up of 6 months from curative treatment (RC or BP) and without disease were eligible for inclusion. Two HRQOL instruments were administered: Bladder Cancer Index (BCI) for bladder cancer-specific HRQOL and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

View Article and Find Full Text PDF

Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.

BMJ Oncol

August 2024

Cyrus Tang Medical Institute, State Key Laboratory of Radiation Medicine and Prevention, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu, China.

Objective: Current biomarkers for predicting immunotherapy response in non-small-cell lung cancer (NSCLC) are derived from invasive procedures with limited predictive accuracy. Thus, identifying a non-invasive predictive biomarker would improve patient stratification and precision immunotherapy.

Methods And Analysis: In this retrospective multicohort study, the discovery cohort included 205 NSCLC patients screened from ORIENT-11 and an external validation (EV) cohort included 99 real-world NSCLC patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!